Patents Assigned to Roche GlycArt AG
  • Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
    Patent number: 9631023
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: April 25, 2017
    Assignee: ROCHE GLYCART AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey
  • A-FUCOSYLATION DETECTION IN ANTIBODIES
    Publication number: 20170108510
    Abstract: This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.
    Type: Application
    Filed: June 10, 2016
    Publication date: April 20, 2017
    Applicant: Roche Glycart AG
    Inventors: Christiane Jaeger, Hans Koll, Peter Sondermann, Pablo Umana
  • Anti-HER3 antibodies and uses thereof
    Patent number: 9611331
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: April 4, 2017
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • NOVEL IMMUNOCONJUGATES
    Publication number: 20170088631
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Application
    Filed: July 1, 2016
    Publication date: March 30, 2017
    Applicant: Roche Glycart AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • COMBINATION IL-2 IMMUNOCONJUGATE THERAPY
    Publication number: 20170056522
    Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 2, 2017
    Applicant: Roche Glycart AG
    Inventors: Christian Gerdes, Christian Klein, Valeria G. Nicolini, Pablo Umana
  • Combination IL-2 immunoconjugate therapy
    Patent number: 9526797
    Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: December 27, 2016
    Assignee: Roche Glycart AG
    Inventors: Christian Gerdes, Christian Klein, Valeria G. Nicolini, Pablo Umana
  • DR5—FAP bispecific death receptor agonistic antibodies
    Patent number: 9481730
    Abstract: The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: November 1, 2016
    Assignee: Roche Glycart AG
    Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau, Sylvia Herter, Christoph Lampert, Ekkehard Moessner, Pablo Umana, Inja Waldhauer
  • Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity
    Publication number: 20160272719
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 22, 2016
    Applicant: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey
  • Immunoconjugates
    Patent number: 9447159
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: September 20, 2016
    Assignee: Roche Glycart AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE
    Publication number: 20160264651
    Abstract: The invention provides antibodies against the A2 domain of tenascin-C and methods of using the same.
    Type: Application
    Filed: September 2, 2015
    Publication date: September 15, 2016
    Applicant: Roche Glycart AG
    Inventors: Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña
  • NOVEL IMMUNOCONJUGATES
    Publication number: 20160263240
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Application
    Filed: January 15, 2016
    Publication date: September 15, 2016
    Applicant: Roche Glycart AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • ANTI-CEA ANTIBODIES
    Publication number: 20160229923
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: October 30, 2015
    Publication date: August 11, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20160208017
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: January 15, 2016
    Publication date: July 21, 2016
    Applicant: Roche Glycart AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
    Publication number: 20160208009
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Application
    Filed: July 10, 2015
    Publication date: July 21, 2016
    Applicant: Roche GlycArt AG
    Inventors: Pablo Umana, Joël Jean-Mairet, James E. Bailey
  • Multispecific antibodies comprising full length antibodies and single chain fab fragments
    Patent number: 9382323
    Abstract: The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 5, 2016
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Peter Bruenker, Rebecca Croasdale, Christian Klein, Erhard Kopetzki, Ekkehard Moessner, Joerg Thomas Regula, Juergen Michael Schanzer, Jan Olaf Stracke, Pablo Umana
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE
    Publication number: 20160166688
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.
    Type: Application
    Filed: May 8, 2014
    Publication date: June 16, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: FRANK HERTING, CHRISTIAN KLEIN
  • Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
    Patent number: 9360481
    Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: June 7, 2016
    Assignee: Roche Glycart AG
    Inventors: Lilla Di Scala, Stefan Evers, Christian Gerdes, Christoph Mancao, Alexandre Passioukov, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20160145354
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: August 25, 2015
    Publication date: May 26, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: MARINA BACAC, PETER BRUENKER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, PABLO UMANA, TINA WEINZIERL
  • Humanized anti-CDCP1 antibodies
    Patent number: 9346886
    Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: May 24, 2016
    Assignee: Roche Glycart AG
    Inventors: Johannes Auer, Birgit Bossenmaier, Guy Georges, Alexander Lifke, Ekkehard Moessner, Gerhard Niederfellner
  • Interleukin-10 fusion proteins
    Patent number: 9346872
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: May 24, 2016
    Assignee: ROCHE GLYCART AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu